Therakind Ltd
R&D/Manufacturing
- Website
- https://www.therakind.com/
- Membership category
- Corporate
Third Floor, 314 Regents Park Road, London, N3 2JX, United Kingdom
Therakind Ltd at a glance
Therakind is a specialty pharmaceutical company, focused on developing medicines in difficult-to-treat markets including paediatric and geriatric patients groups. Therakind has successfully brought three products to approval in the EU/UK.
About Therakind Ltd
Therakind is a specialty pharmaceutical company focussed on developing niche medicines in difficult-to-treat markets including paediatric and geriatric patient groups and those suffering from chronic illness.
We have an innovative approach to medicine design and we are passionate about delivering life changing medicines for all.
With a strong track record in the research and development of innovative medicines and drug delivery systems, our projects are designed specifically to take into account the pharmacodynamics and pharmacokinetics of difficult-to-treat patient groups.
Our clinical programmes are significantly de-risked compared to traditional biotech and pharma models by reformulating existing, approved products with proven safety and efficacy profiles, resulting in specially designed medicines to maximise efficacy and ease of use and thereby improve treatment adherence and disease management.
We have developed and obtained marketing authorisations for three paediatric products, with Jylamvo, our European approved oral methotrexate solution for treating rheumatological and dermatological diseases and acute lymphoblastic leukaemia, also licensed for adults.
DriDose®, our intranasal device for the delivery of a dry powder drug formulation is available for co-development
Our expertise is the ability to design, develop and take new formulations to regulatory approval and beyond utilising our wealth of experience in drug formulation, drug delivery, clinical, commercial and regulatory strategy, project management, clinical study design, management, analysis and reporting, and securing clinical trial and marketing authorisations
